GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

Have you ever wondered how an Alzheimer’s patient literally views the world and what they experience in the confusion? Now, families and caregivers can have the experience through special goggles ...

Over seven million Americans currently have Alzheimer disease (AD). That’s according to the Alzheimer’s Association. One out of every nine seniors over 65 will experience some degree of dementia.

Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing them to receive a diagnosis.

Reviewed by Anton Porsteinsson, MD, Director of the University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE) in New York; and the first William B. and Sheila Konar, ...

Professor Fiona Carragher, chief policy and research officer at Alzheimer’s Society, said: “Rapid advancements in AI will give people affected by early-stage dementia the opportunity to stay safely in ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

Now, with the passing of House Bill 565, also known as Jill’s Law, all Mississippians will have access to biomarker testing ...